Go to the M. D. Anderson Home Page

Back to the PTSG Home Page


News and Progress
Pancreatic Cancer - Frequently Asked Questions
Diagnosis and Treatment
Clinical Studies

Category A

Category B
Category C
Category D
Who are the Pancreatic Tumor Study Group specialists?
How to refer a patient for evaluation
Pancreas Cancer Survivors
From Bench to Bedside: Basic Science Research
PTSG Top Web Picks


Clinical Studies for
Patients with Pancreatic Cancer

Category D


These studies are for patients with advanced disease (metastatic).

A NOTE ABOUT SOME PHASE I TRIALS:

Some of the Phase I trials listed here are not conducted by the Gastrointestinal Oncology Department or the Pancreatic Study Group. Some are run by other departments at M. D. Anderson and have opened them to a wide variety of solid-tumor cancers, including pancreatic. If you choose to call New Patient Referral about any of the protocols on this page, make sure you know the following:

  • The Study Chairman
  • The Name and Number of the Protocol
  • The Research Nurse (if noted in protocol information)

This will help the New Patient Referral office direct you to the right Referral specialist and the right clinic to discuss the treatment trial.

Protocol IDP99-043: Pilot Study of Flt-3 Ligand in Patients with Peritoneal Carcinomatosis Associated with Müllerian and Gastrointestinal Carcinomas

Protocol DM99-416: A Phase II Open-Label Study of SCH66336 in Combination with Gemcitabine in Patients with Metastatic Adenocarcinoma of the Pancreas

Protocol ID99-147: Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody C225 in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer This trial is now closed to new patient entry.

Protocol ID99-095: Herceptin (NSC # 688097) and Gemcitabine for Metastatic Pancreatic Cancers that Overexpress HER-2/neu

Protocol DM98-071: Phase II Study of Dolastatin 10 (NSC#376128) Administered Intravenously Every 21 Days to Patients with Metastatic Pancreatic Adenocarcinoma. The Dolastatin 10 trial is on hold, pending review of the preliminary data.

Protocol DM97-246: Phase II Study of CPT-11 in Patients with Metastatic, Unresectable Carcinoid Tumors or Islet Cell Carcinoma

Protocol ID99-166: Phase I Study of 9-nitro-20(s)-camptothecin (Rubetican) in Combination with Cisplatin for Patients with Advanced Malignancies